Publication: Comprehensive Analysis of Nivolumab, A Therapeutic Anti-Pd-1 Monoclonal Antibody: Impact of Handling and Stress.
dc.contributor.author | Torrente-Lopez, Anabel | |
dc.contributor.author | Hermosilla, Jesus | |
dc.contributor.author | Salmeron-Garcia, Antonio | |
dc.contributor.author | Cabeza, Jose | |
dc.contributor.author | Navas, Natalia | |
dc.contributor.funder | I+D+i—Junta de Andalucía, Spain | |
dc.contributor.funder | Universidad de Granada, Proyectos I+D+i del Programa Operativo FEDER Andalucía 2020 | |
dc.contributor.funder | European Regional Development Funds. | |
dc.date.accessioned | 2023-05-03T14:20:53Z | |
dc.date.available | 2023-05-03T14:20:53Z | |
dc.date.issued | 2022-03-17 | |
dc.description.abstract | Nivolumab, formulated in the medicine Opdivo® (10 mg/mL), is a therapeutic monoclonal antibody (mAb) used in the treatment of different types of cancer. Currently, there is insufficient knowledge about the behaviour of this protein with regards to the risk associated with its routine handling or unintentional mishandling, or when subjected to stress conditions in hospitals. These conditions can be simulated in forced degradation studies, which provide an in-depth understanding of the biophysical and biochemical properties of mAbs. In this study, we carried out a physicochemical and functional characterisation of nivolumab, which was subjected to various stress conditions: heat, freeze/thaw cycles, agitation, light exposure and high hypertonic solution. We used a wide range of analytical techniques: Far-UV CD, IT-FS, DLS, SE/UHPLC(UV)-[Native]MS, and ELISA. The results show that exposure to light was the stress test with the greatest impact on the samples, revelling the formation of non-natural dimers and a different isoform profile. In addition, nivolumab (Opdivo®) demonstrated stability up to 60 °C (1 h). As regards functionality all the nivolumab (Opdivo®) stressed samples were found to be stable except for those subjected to light and agitation, and to a lesser extent, those subjected to FTC 5 and NaCl stresses. | |
dc.description.version | Si | |
dc.identifier.citation | Torrente-López A, Hermosilla J, Salmerón-García A, Cabeza J, Navas N. Comprehensive Analysis of Nivolumab, A Therapeutic Anti-Pd-1 Monoclonal Antibody: Impact of Handling and Stress. Pharmaceutics. 2022 Mar 23;14(4):692 | |
dc.identifier.doi | 10.3390/pharmaceutics14040692 | |
dc.identifier.issn | 1999-4923 | |
dc.identifier.pmc | PMC9025134 | |
dc.identifier.pmid | 35456527 | |
dc.identifier.pubmedURL | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9025134/pdf | |
dc.identifier.unpaywallURL | https://www.mdpi.com/1999-4923/14/4/692/pdf?version=1648033999 | |
dc.identifier.uri | http://hdl.handle.net/10668/21547 | |
dc.issue.number | 4 | |
dc.journal.title | Pharmaceutics | |
dc.journal.titleabbreviation | Pharmaceutics | |
dc.language.iso | en | |
dc.organization | Hospital Universitario San Cecilio | |
dc.organization | Hospital Universitario San Cecilio | |
dc.organization | Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA) | |
dc.page.number | 22 | |
dc.provenance | Realizada la curación de contenido 08/08/2024 | |
dc.publisher | MDPI AG | |
dc.pubmedtype | Journal Article | |
dc.relation.projectID | P20-01029 | |
dc.relation.projectID | B-FQM-308-UGR20 | |
dc.relation.publisherversion | https://www.mdpi.com/resolver?pii=pharmaceutics14040692 | |
dc.rights | Attribution 4.0 International | |
dc.rights.accessRights | open access | |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
dc.subject | UHPLC-MS | |
dc.subject | comprehensive analytical characterisation | |
dc.subject | forced degradation | |
dc.subject | isoform profile | |
dc.subject | nivolumab | |
dc.subject.decs | Anticuerpos monoclonales | |
dc.subject.decs | Cloruro de sodio | |
dc.subject.decs | Cromatografía líquida de alta presión | |
dc.subject.decs | Ensayo de inmunoadsorción enzimática | |
dc.subject.decs | Hospitales | |
dc.subject.decs | Isoformas de proteínas | |
dc.subject.decs | Neoplasias | |
dc.subject.decs | Nivolumab | |
dc.subject.decs | Prueba de esfuerzo | |
dc.subject.mesh | Nivolumab | |
dc.subject.mesh | Antibodies, Monoclonal | |
dc.subject.mesh | Sodium Chloride | |
dc.subject.mesh | Chromatography, High Pressure Liquid | |
dc.subject.mesh | Exercise Test | |
dc.subject.mesh | Neoplasms | |
dc.subject.mesh | Protein Isoforms | |
dc.subject.mesh | Enzyme-Linked Immunosorbent Assay | |
dc.subject.mesh | Hospitals | |
dc.title | Comprehensive Analysis of Nivolumab, A Therapeutic Anti-Pd-1 Monoclonal Antibody: Impact of Handling and Stress. | |
dc.type | research article | |
dc.type.hasVersion | VoR | |
dc.volume.number | 14 | |
dspace.entity.type | Publication |